How does TCR-T cell therapy exhibit a superior anti-tumor efficacy

Yang, Dandan; Duan, Zhihui; Yuan, Ping; Ding, Chengming; Dai, Xiaoming; Chen, Guodong; Wu, Daichao

doi:10.1016/j.bbrc.2023.149209

Cited by 2 publications

(2 citation statements)

References 148 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…TCR-T cells can recognize a broad spectrum of antigen peptides presented by MHC molecules, including tumor cell surface antigens, intracellular antigens and neoantigens resulting from tumor mutations [ 120 ]. Given the fact that most proteins are expressed intracellularly and CAR-T cells only identify cell surface antigens, TCR-T thereby has a wider tumor antigen selectivity than CAR-T, whereas CAR-T cells are superior to TCR-T cells in terms of target affinity and therapeutic dosage [ 121 ]. Both regimens have shown remarkable effectiveness in treating hematological malignancies [ 122 ].…”

Section: Cancer Immunotherapy Involving Cd8 + T Cellsmentioning

confidence: 99%

CD8+ T cell-based cancer immunotherapy

Chen,

Yu,

Qian

et al. 2024

J Transl Med

View full text Add to dashboard Cite

The immune system in humans is a defense department against both exogenous and endogenous hazards, where CD8+ T cells play a crucial role in opposing pathological threats. Various immunotherapies based on CD8+ T cells have emerged in recent decades, showing their promising results in treating intractable diseases. However, in the fight against the constantly changing and evolving cancers, the formation and function of CD8+ T cells can be challenged by tumors that might train a group of accomplices to resist the T cell killing. As cancer therapy stepped into the era of immunotherapy, understanding the physiological role of CD8+ T cells, studying the machinery of tumor immune escape, and thereby formulating different therapeutic strategies become the imperative missions for clinical and translational researchers to fulfill. After brief basics of CD8+ T cell-based biology is covered, this review delineates the mechanisms of tumor immune escape and discusses different cancer immunotherapy regimens with their own advantages and setbacks, embracing challenges and perspectives in near future.

show abstract

Section: Cancer Immunotherapy Involving Cd8 + T Cellsmentioning

confidence: 99%

CD8+ T cell-based cancer immunotherapy

Chen,

Yu,

Qian

et al. 2024

J Transl Med

View full text Add to dashboard Cite

show abstract

“…Protein post-translational modifications (PTMs) are present in multiple autoimmune diseases and tumors. Protein phosphorylation, sumoylation, and acetylation may offer new targets for TCR-T cell therapy [91] . An antigen discovery pipeline called Protein Modification Integrated Search Engine (PROMISE) could help identify thousands of new cancer-specific PTM antigens [92] .…”

Section: Tumor Antigensmentioning

confidence: 99%

The recent advancement of TCR-T cell therapies for cancer treatment

Zhao*,

Shao,

2024

ABBS

View full text Add to dashboard Cite

Adoptive cell therapies involve infusing engineered immune cells into cancer patients to recognize and eliminate tumor cells. Adoptive cell therapy, as a form of living drug, has undergone explosive growth over the past decade. The recognition of tumor antigens by the T-cell receptor (TCR) is one of the natural mechanisms that the immune system used to eliminate tumor cells. TCR-T cell therapy, which involves introducing exogenous TCRs into patients' T cells, is a novel cell therapy strategy. TCR-T cell therapy can target the entire proteome of cancer cells. Engineering T cells with exogenous TCRs to help patients combat cancer has achieved success in clinical trials, particularly in treating solid tumors. In this review, we examine the progress of TCR-T cell therapy over the past five years. This includes the discovery of new tumor antigens, protein engineering techniques for TCR, reprogramming strategies for TCR-T cell therapy, clinical studies on TCR-T cell therapy, and the advancement of TCR-T cell therapy in China. We also propose several potential directions for the future development of TCR-T cell therapy.

show abstract

How does TCR-T cell therapy exhibit a superior anti-tumor efficacy

Cited by 2 publications

References 148 publications

CD8+ T cell-based cancer immunotherapy

CD8+ T cell-based cancer immunotherapy

The recent advancement of TCR-T cell therapies for cancer treatment

Contact Info

Product

Resources

About